Disclosed herein is method and system for evaluating semen quality. Plurality of images of stained semen sample are captured and analyzed for eliminating unusable images. Further, visible objects in the images are extracted and classified into sperm objects and non-sperm objects. The sperm objects are further classified into normal/abnormal sperm objects based on morphological characteristics of sperm objects, and a differential count of normal/abnormal sperm objects is determined. Subsequently, an aggregate count of the non-sperm objects is determined. Finally, a sperm quality index, indicative of quality of the semen sample, is computed based on morphological characteristics of sperm objects, differential count of normal/abnormal sperm objects, aggregate count of non-sperm objects and total motility estimate of semen sample. The method of present disclosure helps in accurate estimation of the semen quality, since the aggregate count of the non-sperm objects is considered as a crucial parameter for computing the semen quality index.

A device includes an input chamber, an attractant chamber, a migration channel arranged in fluid communication between an outlet of the input chamber and inlet of the attractant chamber, a baffle arranged in fluid communication between the outlet of the input chamber and the migration channel or within the migration channel, and an exit channel in fluid communication with the migration channel at a point beyond the baffle and before the migration channel enters the inlet of the attractant chamber. The baffle is configured to inhibit movement of a first type of cell through the baffle to a greater extent than the baffle inhibits movement of a second type of cell through the baffle.

A measurement device includes a stimulus control unit configured to cause a stimulus generation device to generate an external stimulus complying with a chemotaxis condition of an organism, an imaging unit configured to capture an image of a predetermined imaging range in which the external stimulus is generated, and a measurement unit configured to measure a target organism on the basis of the image captured by the imaging unit.

The present invention relates to a therapeutic agent for immune cell migration-caused disease and a method for screening the same and, more particularly, to a pharmaceutical composition comprising a KRS inhibitor (or expression or activity inhibitor) as an effective ingredient for preventing or treating an immune cell migration-related disease, a method for controlling the migration of immune cells by regulating a level of KRS in immune cells, a cell membrane site-specific moiety level of KRS or the migration of KRS to the cell membrane, and a method for screening a therapeutic agent for immune cell migration-caused disease, using KRS. According to the present invention, the migration of immune cells can be controlled by means of KRS, which can find very useful applications in the prevention, alleviation, and treatment of immune cell migration-related disease.

A method of assaying metastasis can include: providing a device of one of the embodiments; introducing the at least one cancer cell into the at least one internal chamber or at least one fluid channel; and studying metastasis of the at least one cancer cell. Optionally: introducing cancer cells into a first internal chamber; detecting escape of the cancer cell from the first internal chamber into the fluid channel; detecting migration of the cancer cell through the fluid channel; detecting adhesion of the cancer cell to a coating on the fluid channel; detecting invasion of the cancer cell into a second internal chamber from the fluid channel; or visualizing metastasis of the cancer cell with a visualization device.

Disclosed herein are compositions and methods for cellular reconstitution of photopolymerized, lyophilized, bioactive chondroitin sulfate glycosaminoglycan (CS-GAG)-based hydrogel matrices.

Among the various aspects of the present disclosure is the provision of a hydrogel-based substrate comprising an aldehyde-containing component, such as N-ethanal acrylamide. The hydrogel component allows for functionalization of a hydrogel through conjugation of proteins (e.g., collagen) to the hydrogel in the absence of a post hoc crosslinking component.

A cell analysis system according to the present disclosure includes a motion information extracting unit and a motion characteristics calculating unit. The motion information extracting unit extracts motion information arising from a movement of ions or molecules across a cell membrane, out of a cell image obtained from imaging a cell in time series. The motion characteristics calculating unit calculates motion characteristics of the motion information.

Disclosed herein are bioreactor systems and methods of utilizing said systems.

Disclosed is a marker for observing an effect of a compound or a drug on cells in real time. The marker is: 1) an amino acid sequence shown in SEQ No. 1 and/or SEQ No. 2; or 2) an amino acid sequence having a function for observing an effect of a compound or a drug on cells in real time and having at least more than 80%, preferably more than 85%, more preferably 90%, further preferably 95%, and most preferably 99% homology with the amino acid sequence shown in SEQ No. 1 and/or SEQ No. 2. Also disclosed is a method and a kit for observing an effect of a compound or a drug on cells in real time and use thereof